Takeda N, Nakamura I, Hatanaka T, Iwai T, Tanamura A, Obara Y, Nagano M
Department of Internal Medicine, Aoto Hospital, Jikei University School of Medicine, Tokyo, Japan.
Basic Res Cardiol. 1991;86 Suppl 3:197-202. doi: 10.1007/978-3-662-30769-4_19.
The effects of long-term treatment of hypertensive patients with alacepril (angiotensin-converting enzyme inhibitor) on cardiac mass and function were investigated. A total of 12 patients was examined. Both systolic and diastolic blood pressure were significantly reduced by treatment with alacepril for 1 year. Left ventricular mass, as estimated by echocardiography, was significantly decreased by alacepril treatment, although electrocardiographic and chest x-ray findings were not significantly altered. Cardiac pump function, which was also assessed by echocardiography, was not changed. These results indicate that long-term treatment of hypertension with alacepril induces regression of cardiac hypertrophy without any change in cardiac contractile function.
研究了用阿拉普利（一种血管紧张素转换酶抑制剂）对高血压患者进行长期治疗对心脏质量和功能的影响。共检查了12例患者。用阿拉普利治疗1年后，收缩压和舒张压均显著降低。通过超声心动图估计，阿拉普利治疗使左心室质量显著降低，尽管心电图和胸部X线检查结果无明显改变。同样通过超声心动图评估的心脏泵功能未改变。这些结果表明，用阿拉普利长期治疗高血压可使心脏肥大消退，而心脏收缩功能无任何变化。
